PRLR and breast carcinoma: A preclinical study of the anti-PRLR antibody REGN2878-DM1 suggested induction of cell-cycle arrest and apoptosis in PRLR expressing breast cancer cell lines, and also exhibited synergistic activity with fulvestrant (31).